Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

10.58
-0.1900-1.76%
Pre-market: 10.50-0.0800-0.76%05:22 EDT
Volume:3.72M
Turnover:38.27M
Market Cap:900.43M
PE:-2.77
High:10.80
Open:10.75
Low:10.00
Close:10.77
52wk High:23.29
52wk Low:8.80
Shares:85.11M
Float Shares:55.47M
Volume Ratio:1.97
T/O Rate:6.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8139
EPS(LYR):-3.5300
ROE:-67.47%
ROA:-32.44%
PB:2.10
PE(LYR):-3.00

Loading ...

MoonLake Immunotherap Is Maintained at Buy by Needham

Dow Jones
·
May 12

Needham Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
May 12

MoonLake Immunotherapeutics : Needham Raises Target Price to $30 From $25

THOMSON REUTERS
·
May 12

MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained

TIPRANKS
·
May 12

Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential

TIPRANKS
·
May 11

MoonLake Q1 net loss widens 71.9% to $69.7 million

Reuters
·
May 11

MoonLake Immunotherapeutics reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Axsome Therapeutics (AXSM)

TIPRANKS
·
May 11

MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 11

MoonLake Immunotherapeutics Q1 Net Loss Widens

MT Newswires Live
·
May 11

MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street

TIPRANKS
·
May 11

MoonLake says aligned with FDA on submission plans for sonelokimab

TIPRANKS
·
May 11

MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year

TIPRANKS
·
May 11

MoonLake says FDA backs sonelokimab HS BLA plan, filing set for September 2026

Reuters
·
May 10

Moonlake Immunotherapeutics Says U.S. FDA Accepts MIRA And VELA-TEEN Trial Data For Sonelkimab BLA Submission

Reuters
·
May 10

MoonLake Immunotherapeutics - FDA Accepts Mira and Vela-Teen Trial Data for Sonelkimab Bla Submission

THOMSON REUTERS
·
May 10

MoonLake Immunotherapeutics Announces Positive Outcome From Its Final Pre-Bla Meeting With the U.S. FDA and Reports First Quarter 2026 Financial Results

THOMSON REUTERS
·
May 10

MoonLake Immunotherapeutics - Bla Submission for Sonelkimab in Hs Planned for End of September 2026

THOMSON REUTERS
·
May 10

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 10

Moonlake Immunotherapeutics announces annual shareholder meeting

Reuters
·
Apr 22